Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PF-07799933 |
Synonyms | |
Therapy Description |
PF-07799933 is an ATP-competitive RAF inhibitor with activity against BRAF mutations, which may lead to inhibition of tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr TPS3164). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07799933 | PF07799933|PF 07799933|ARRY440|ARRY 440|ARRY-440 | BRAF Inhibitor 25 | PF-07799933 is an ATP-competitive RAF inhibitor with activity against BRAF mutations, which may lead to inhibition of tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr TPS3164). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05355701 | Phase I | Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Recruiting | USA | CAN | 1 |